Shares in Moderna (Nasdaq: MRNA) were up by nearly a quarter at lunchtime Tuesday.
The US mRNA specialist had just announced a major cancer breakthrough alongside pharma partner Merck & Co (NYSE: MRK), which itself was trading more than 1% higher at the same moment.
They revealed that the success of the Phase IIb KEYNOTE-942/mRNA-4157-P201 trial of mRNA- 4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze